• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性脑梗死患者血浆纤溶功能分析

Analysis of plasma fibrinolysis in the patients with acute cerebral infarction.

作者信息

Shang Y D, Liu X M, Cai Z, Yang M S

机构信息

Department of Neurology, Tongji Hospital, Tongji Medical University, Wuhan.

出版信息

J Tongji Med Univ. 1995;15(2):68-72. doi: 10.1007/BF02887904.

DOI:10.1007/BF02887904
PMID:8731955
Abstract

In the present study, the plasma fibrinolytic activity in 30 cases of cortical artery territory cerebral infarction (CACI) and 32 cases of perforating artery territory cerebral infarction (PACI) within 3 days after ictus, and 30 sex- and age-matched controls without cardio-cerebrovascular diseases were evaluated by a comprehensive panel of assay, including the plasma tPA activity, PAI activity, endothelial capacity of tPA release and PAI/tPA ratio. The results showed that the plasma fibrinolysis and the endothelial potential to release tPA responding to stimulation in both subtypes of the patients were significantly lower than those in the controls, which provide the theoretical basis for carrying out the thrombolytic therapy in the ischemic stroke. And the study also suggested that increased plasma PAI activity could increase the risk of AS thrombotic events with increased serum triglyceride level.

摘要

在本研究中,对30例皮质动脉区脑梗死(CACI)患者和32例穿支动脉区脑梗死(PACI)患者发病后3天内的血浆纤溶活性进行评估,并与30例无心脑血管疾病、年龄和性别匹配的对照者进行比较,评估项目包括血浆组织型纤溶酶原激活物(tPA)活性、纤溶酶原激活物抑制剂(PAI)活性、tPA释放的内皮能力以及PAI/tPA比值。结果显示,两类患者的血浆纤溶作用以及刺激后内皮释放tPA的能力均显著低于对照组,这为缺血性卒中的溶栓治疗提供了理论依据。该研究还表明,血浆PAI活性增加会随着血清甘油三酯水平升高而增加动脉粥样硬化血栓形成事件的风险。

相似文献

1
Analysis of plasma fibrinolysis in the patients with acute cerebral infarction.急性脑梗死患者血浆纤溶功能分析
J Tongji Med Univ. 1995;15(2):68-72. doi: 10.1007/BF02887904.
2
[An analysis on the activity status of fibrinolytic system in Chinese patients with acute cerebral infarction].[中国急性脑梗死患者纤溶系统活性状态分析]
Zhonghua Nei Ke Za Zhi. 1995 Aug;34(8):518-21.
3
Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.中风患者体内的组织型纤溶酶原激活剂和纤溶酶原激活物抑制剂-1
Stroke. 1996 Jun;27(6):1066-71. doi: 10.1161/01.str.27.6.1066.
4
High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.血浆中纤溶酶原激活物抑制剂和组织纤溶酶原激活物水平升高在男性和女性首次急性心肌梗死之前出现:纤溶系统作为独立主要危险因素的证据。
Circulation. 1998 Nov 24;98(21):2241-7. doi: 10.1161/01.cir.98.21.2241.
5
Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke.组织型纤溶酶原激活剂、纤溶酶原激活剂抑制剂-1以及组织型纤溶酶原激活剂/纤溶酶原激活剂抑制剂-1复合物作为首次中风发生的危险因素。
Stroke. 2000 Jan;31(1):26-32. doi: 10.1161/01.str.31.1.26.
6
[Clinical study on active factors of vascular endothelial cells in acute cerebral infarction patients and therapeutical effect of activating blood stasis].急性脑梗死患者血管内皮细胞活性因子及活血化瘀治疗效果的临床研究
Zhongguo Zhong Xi Yi Jie He Za Zhi. 1998 Jul;18(7):392-5.
7
[Changes in the fibrinolytic activity in hypertension and acute cerebral infarction].[高血压与急性脑梗死中纤溶活性的变化]
Zhonghua Xin Xue Guan Bing Za Zhi. 1993 Jun;21(3):150-2, 186-7.
8
Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.优球蛋白凝块溶解时间与组织型纤溶酶原激活物及纤溶酶原激活物抑制剂1血浆水平之间的关系。
Thromb Haemost. 1990 Feb 19;63(1):82-6.
9
Coagulation and fibrinolytic activity in patients with acute cerebral infarction.急性脑梗死患者的凝血和纤溶活性
Chin Med J (Engl). 2003 Mar;116(3):475-7.
10
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.在斯德哥尔摩心脏流行病学项目(SHEEP)研究中,血浆组织型纤溶酶原激活剂/纤溶酶原激活剂抑制剂-1复合物水平和血管性血友病因子是复发性心肌梗死的重要风险标志物。
Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):2019-23. doi: 10.1161/01.atv.20.8.2019.

本文引用的文献

1
Coagulation abnormalities and cerebral infarction.凝血异常与脑梗死
J Neurol Neurosurg Psychiatry. 1993 May;56(5):433-9. doi: 10.1136/jnnp.56.5.433.
2
Impaired fibrinolysis in coronary artery disease.冠状动脉疾病中的纤维蛋白溶解功能受损。
Am Heart J. 1988 Apr;115(4):776-80. doi: 10.1016/0002-8703(88)90878-2.
3
Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.血浆纤溶酶原激活物抑制剂:复发性心肌梗死的危险因素。
Lancet. 1987 Jul 4;2(8549):3-9. doi: 10.1016/s0140-6736(87)93050-9.
4
Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population.瑞典北部人群中纤溶酶原激活物抑制剂、组织纤溶酶原激活物、脂蛋白(a)的血浆水平与既定心血管危险因素之间的相互关系。
Atherosclerosis. 1989 Nov;80(1):9-16. doi: 10.1016/0021-9150(89)90062-2.
5
Diagnosis and treatment of ischemic stroke.
JAMA. 1991 Nov 6;266(17):2413-8.
6
Thrombolytic therapy in cerebrovascular disorders.脑血管疾病的溶栓治疗。
Prog Cardiovasc Dis. 1992 Jan-Feb;34(4):235-62. doi: 10.1016/0033-0620(92)90020-z.
7
Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity.纤溶酶原激活物抑制剂-1基因座的遗传变异与血浆纤溶酶原激活物抑制剂-1活性水平的改变有关。
Arterioscler Thromb. 1991 Jan-Feb;11(1):183-90. doi: 10.1161/01.atv.11.1.183.
8
The plurality of subcortical infarction.
Stroke. 1992 May;23(5):629-31. doi: 10.1161/01.str.23.5.629.
9
The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review.纤溶酶原激活物抑制剂-1作为动脉和血栓性疾病危险因素的现状:综述
Atherosclerosis. 1992 Aug;95(2-3):105-17. doi: 10.1016/0021-9150(92)90014-8.
10
Hypertriglyceridemia and regulation of fibrinolytic activity.高甘油三酯血症与纤溶活性的调节
Arterioscler Thromb. 1992 Jan;12(1):19-27. doi: 10.1161/01.atv.12.1.19.